The DOI matches its Crossref record.
Duloxetine for the Treatment of Major Depressive Disorder
Abstract
Background. Existing therapies for depression frequently fail to provide full remission. This report evaluates the efficacy and safety of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine, in the treatment of major depressive disorder (MDD). Method. Efficacy of duloxetine was evaluated in six double-blind, placebo- and/or active-comparator-controlled clinical trials. A study of duloxetine in patients with stress urinary incontinence was also included in the safety assessments. The primary efficacy measure was total score on the 17-item Hamilton Rating Scale for Depression (HAMD-17). Secondary measures included estimated probabilities of response and remission, and changes in the Clinical Global Impressions scale, Patients Global Impression scale, and the Hamilton Rating Scale for Anxiety. Physical symptoms were assessed using Visual Analog Scales for Pain. Safety evaluations included reporting of adverse events, changes in vital signs, electrocardiogram, blood pressure, and laboratory analyses. Results. Duloxetine was significantly superior to placebo in reducing mean HAMD-17 total score in four of the six studies. Significant improvements for duloxetine over placebo were also observed on many secondary efficacy measures across five of the studies. Probabilities of remission >55% were observed in two of the studies, while in a third study the probability of remission with duloxetine treatment was nearly three times that observed with placebo (44% versus 16%). Duloxetine also produced significant improvement in painful physical symptoms compared with placebo, in many cases after only 2 weeks of treatment. The discontinuation rate due to adverse events (14.6%) was similar to those observed with selective serotonin reuptake inhibitors. The most frequently reported adverse events were nausea, dry mouth, fatigue, and insomnia. Conclusion. Duloxetine was demonstrated to be safe and effective in the treatment of MDD. The starting dose with the best balance of efficacy and tolerability is 60 mg per day. Psychopharmacology Bulletin. 2002;36(4):106-132
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Duloxetine vs. placebo in patients with painful diabetic neuropathy
Goldstein, D. J., Lu, Y., Detke, M. J., Lee, T. C., & Iyengar, S. (2005) · Pain · doi:10.1016/j.pain.2005.03.029 · Cited by 858
Self-citationRaskin, J., Pritchett, Y. L., Wang, F., D'Souza, D. N., Waninger, A. L., Iyengar, S., & Wernicke, J. F. (2005) · Pain Medicine · doi:10.1111/j.1526-4637.2005.00061.x · Cited by 532
A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain
Wernicke, J. F., Pritchett, Y. L., D’Souza, D. N., Waninger, A., Tran, P., Iyengar, S., & Raskin, J. (2006) · Neurology · doi:10.1212/01.wnl.0000240225.04000.1a · Cited by 510
Nutt, D., Demyttenaere, K., Janka, Z., Aarre, T., Bourin, M., Canonico, P. L., Carrasco, J. L., & Stahl, S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106069938 · Cited by 366
The burden of severe depression: A review of diagnostic challenges and treatment alternatives
Nemeroff, C. B. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.05.008 · Cited by 295
Self-citation
Metadata
- Authors
- Nemeroff, C. B., MD, PhD, Schatzberg, A. F., MD, Goldstein, D. J., MD, PhD, Detke, M. J., MD, PhD, Mallinckrodt, C., PhD, Lu, Y., PhD, Tran, A. P. V., & MD
- Venue
- Psychopharmacology Bulletin
- Publisher
- Medworks Media Inc.
- Published
- 2025-08-12
- Volume
- 36
- Issue
- 4
- Pages
- 106-132
- ISSN
- 0048-5764 (ISSN-L)
- 2472-2448
- OpenAlex
- W72273208
- Cited by
- 175
- References
- 0
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Duloxetine for the Treatment of Major Depressive Disorder. https://app.cochat.ai/papers/10.64719/pb.4207
- The paper
- Nemeroff, C. B., MD, PhD, Schatzberg, A. F., MD, Goldstein, D. J., MD, PhD, Detke, M. J., MD, PhD, Mallinckrodt, C., PhD, Lu, Y., PhD, Tran, A. P. V., & MD. (2025). Duloxetine for the Treatment of Major Depressive Disorder. Psychopharmacology Bulletin. https://doi.org/10.64719/pb.4207
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.